|

APL-101 Oral Capsules Clinical Trials

1 actively recruiting trial across 1 location

Also known as: Bozitinib, CBI-3103, CBT-101, PLB-1001, Vebreltinib

Pipeline

Phase 2: 1

Top Sponsors

  • Apollomics Inc.1

Indications

  • Exon 14 Skipping1
  • MET Fusion1
  • MET Alteration1
  • HGF1
  • Gastroesophageal Junction Adenocarcinoma1

Los Angeles, California1 trial

APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors

Cedars-Sinai Medical Center - Samuel Oschin Comprehensive Cancer Institute

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.